Marc Gerson comments on the new biotech tax credit included in the Senate Finance Committee health care reform bill for companies investing in the development of chronic disease therapies. "I imagine that there will be a very detailed and very competitive application process for the new credit, particularly given that it is subject to a $1 billion limitation," said Gerson. He noted that limiting the credit to firms with fewer than 250 employees will limit the number of possible applicants, but that the process will still be competitive.